Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1993 1
1995 4
1997 1
1998 3
2000 2
2001 1
2002 3
2003 2
2004 1
2005 6
2006 2
2007 1
2008 5
2009 5
2010 4
2011 4
2012 5
2013 4
2014 3
2015 6
2016 5
2017 2
2018 2
2019 4
2020 4
2021 5
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: kandler k. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. Diabetes Obes Metab. 2022. PMID: 35441470 Free PMC article. Clinical Trial.
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Garvey WT, et al. Among authors: kandler k. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. Nat Med. 2022. PMID: 36216945 Free PMC article. Clinical Trial.
Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers.
Dorst J, Weydt P, Brenner D, Witzel S, Kandler K, Huss A, Herrmann C, Wiesenfarth M, Knehr A, Günther K, Müller K, Weishaupt JH, Prudlo J, Forsberg K, Andersen PM, Rosenbohm A, Schuster J, Roselli F, Dupuis L, Mayer B, Tumani H, Kassubek J, Ludolph AC. Dorst J, et al. Among authors: kandler k. EBioMedicine. 2023 Apr;90:104521. doi: 10.1016/j.ebiom.2023.104521. Epub 2023 Mar 12. EBioMedicine. 2023. PMID: 36917918 Free PMC article.
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.
Heerspink HJL, Apperloo E, Davies M, Dicker D, Kandler K, Rosenstock J, Sørrig R, Lawson J, Zeuthen N, Cherney D. Heerspink HJL, et al. Among authors: kandler k. Diabetes Care. 2023 Apr 1;46(4):801-810. doi: 10.2337/dc22-1889. Diabetes Care. 2023. PMID: 36801984 Free PMC article.
Low T-cell reactivity to TDP-43 peptides in ALS.
Ramachandran S, Grozdanov V, Leins B, Kandler K, Witzel S, Mulaw M, Ludolph AC, Weishaupt JH, Danzer KM. Ramachandran S, et al. Among authors: kandler k. Front Immunol. 2023 Jul 21;14:1193507. doi: 10.3389/fimmu.2023.1193507. eCollection 2023. Front Immunol. 2023. PMID: 37545536 Free PMC article.
ALS is imprinted in the chromatin accessibility of blood cells.
Kühlwein JK, Ruf WP, Kandler K, Witzel S, Lang C, Mulaw MA, Ekici AB, Weishaupt JH, Ludolph AC, Grozdanov V, Danzer KM. Kühlwein JK, et al. Among authors: kandler k. Cell Mol Life Sci. 2023 Apr 24;80(5):131. doi: 10.1007/s00018-023-04769-w. Cell Mol Life Sci. 2023. PMID: 37095391 Free PMC article.
Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study.
Dorst J, Doenz J, Kandler K, Dreyhaupt J, Tumani H, Witzel S, Schuster J, Ludolph AC. Dorst J, et al. Among authors: kandler k. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):298-302. doi: 10.1136/jnnp-2021-328331. Epub 2022 Jan 12. J Neurol Neurosurg Psychiatry. 2022. PMID: 35022317 Clinical Trial.
Effects of tofersen treatment in patients with SOD1-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access program.
Wiesenfarth M, Dorst J, Brenner D, Elmas Z, Parlak Ö, Uzelac Z, Kandler K, Mayer K, Weiland U, Herrmann C, Schuster J, Freischmidt A, Müller K, Siebert R, Bachhuber F, Simak T, Günther K, Fröhlich E, Knehr A, Regensburger M, German A, Petri S, Grosskreutz J, Klopstock T, Reilich P, Schöberl F, Hagenacker T, Weyen U, Günther R, Vidovic M, Jentsch M, Haarmeier T, Weydt P, Valkadinov I, Hesebeck-Brinckmann J, Conrad J, Weishaupt JH, Schumann P, Körtvélyessy P, Meyer T, Ruf WP, Witzel S, Senel M, Tumani H, Ludolph AC. Wiesenfarth M, et al. Among authors: kandler k. EClinicalMedicine. 2024 Feb 15;69:102495. doi: 10.1016/j.eclinm.2024.102495. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38384337 Free PMC article.
94 results